NCT01192802

Brief Summary

Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Aug 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 31, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 1, 2010

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

January 24, 2013

Status Verified

January 1, 2013

Enrollment Period

1.9 years

First QC Date

August 31, 2010

Last Update Submit

January 23, 2013

Conditions

Keywords

albendazoleascaristrichiurushookworms

Outcome Measures

Primary Outcomes (1)

  • parasite cleared and reduced up to 80% at day 42

    42 days

Secondary Outcomes (1)

  • Prevalence of major gut bacteria

    42 days

Study Arms (3)

1 dose, Albendazole , tablet

ACTIVE COMPARATOR
Drug: albendazole

2 doses, albendazole, tablet

ACTIVE COMPARATOR

1 tablet of 400 mg of albendazole per day for two consecutive days

Drug: albendazole

3 doses albendazole, 400mg, tablet

ACTIVE COMPARATOR
Drug: albendazole

Interventions

1 tablet of 400 mg of albendazole per day for three consecutive days

3 doses albendazole, 400mg, tablet

Eligibility Criteria

Age4 Years - 14 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • presence of intestinal helminths eggs in the stool

You may not qualify if:

  • allergy to imidazole derivate
  • No intestinal helminths

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical research Unit of Lambaréné

Lambaréné, Moyen-Ogooué Province, 118, Gabon

Location

Related Publications (1)

  • Adegnika AA, Zinsou JF, Issifou S, Ateba-Ngoa U, Kassa RF, Feugap EN, Honkpehedji YJ, Dejon Agobe JC, Kenguele HM, Massinga-Loembe M, Agnandji ST, Mordmuller B, Ramharter M, Yazdanbakhsh M, Kremsner PG, Lell B. Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection. Antimicrob Agents Chemother. 2014 May;58(5):2535-40. doi: 10.1128/AAC.01317-13. Epub 2014 Feb 18.

Related Links

MeSH Terms

Conditions

Intestinal DiseasesHelminthiasisHookworm Infections

Interventions

Albendazole

Condition Hierarchy (Ancestors)

Gastrointestinal DiseasesDigestive System DiseasesParasitic DiseasesInfectionsStrongylida InfectionsSecernentea InfectionsNematode Infections

Intervention Hierarchy (Ancestors)

CarbamatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 31, 2010

First Posted

September 1, 2010

Study Start

August 1, 2010

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

January 24, 2013

Record last verified: 2013-01

Locations